摘要
目的:探讨晚期表皮生长因子受体(EGFR)突变非小细胞肺癌(NSCLC)患者接受吉非替尼靶向治疗后对其生存质量及无进展生存期的影响。方法:选取2018年1月至2021年1月本院肿瘤科收治的120例晚期EGFR突变NSCLC患者作为研究对象。根据治疗手段,将其分为观察组(n=61,采用常规化疗联合吉非替尼治疗)与对照组(n=59,采用常规化疗方案)。比较两组患者临床疗效、总生存期、肿瘤无进展生存期、生存质量以及不良反应发生情况。结果:观察组患者临床总有效率高于对照组,不良反应总发生率低于对照组,差异均有统计学意义(P<0.05)。观察组患者总生存期、肿瘤无进展生存期均长于对照组,差异均有统计学意义(P<0.05)。两组患者治疗后肺癌患者生活质量测定量表(FACT-L)各维度评分均升高,且观察组高于对照组,差异均有统计学意义(P<0.05)。结论:相较于单一化疗,增加吉非替尼靶向治疗可进一步提高EGFR突变NSCLC患者的临床效果,在提升患者生存质量、延长无进展生存期中有积极作用。
Objective:To explore the effect of gefitinib targeted therapy on quality of life and progression-free survival in patients with advanced epidermal growth factor receptor(EGFR)mutant non-small cell lung cancer(NSCLC).Methods:A total of 120 patients with advanced EGFR mutant NSCLC admitted to the oncology department of our hospital from January 2018 to January 2021 were selected as study subjects.According to treatment methods,they were divided into observation group(n=61,received routine chemotherapy and gefitinib)and control group(n=59,received routine chemotherapy).The clinical efficacy,overall survival,tumor progression-free survival,quality of life and adverse reactions were compared between the two groups.Results:The clinical total effective rate of observation group was higher than that of control group,and the total incidence of adverse reactions was lower than that of control group,and the differences were statistically significant(P<O.05).The overall survival and progression-free survival of observation group were longer than those in control group,and the differences were statistically significant(P<0.05).After treatment,the functional assessment of cancer therapy-lung(FACT-L)scores of both groups increased,and observation group was higher than control group,and the differences were statistically significant(P<0.05).Conclusion:Compared with chemotherapy alone,the addition of gefitinib targeted therapy can further improve the clinical efficacy of NSCLC patients with EGFR mutation,and has a positive role in improving the quality of life and prolonging the progression-free survival.
作者
朱春
孙亮起
屈佳
张丽
ZHU Chun;SUN Liangqi;QU Jia;ZHANG Li(Department of Interventional Oncology,Henan Shenhuo Group General Hospital,Shangqiu 476600,China;Department of Respiratory Medicine,Henan Shenhuo Group General Hospital,Shangqiu 476600,China)
出处
《四川解剖学杂志》
2025年第4期34-36,65,共4页
Sichuan Journal of Anatomy
关键词
表皮生长因子受体突变
非小细胞肺癌
吉非替尼
靶向治疗
生存质量
无进展生存期
Epidermal growth factor receptor mutation
Non-small cell lung cancer
Gefitinib
Targeted therapy
Quality of life
Progression-free survival
